Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageLivaNova PLC is a market-leading global medical technology company. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.”
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Jun 2026 · $199.3MThe company’s own SEC segment disclosure.
- Neuromodulation$126.6M63%
- Cardiopulmonary$72.8M37%
LivaNova PLC (LIVN) reported revenue of $362M in Q1 2026 (quarter ended Mar 31, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 67% and net income of $22M (6.2% of revenue). For the full year FY2025, revenue was $1.39B (+11% year on year) and net income −$242M. Its largest segment in Jun 2026 was Neuromodulation at $127M, 63% of the disclosed total, well ahead of Cardiopulmonary at 37%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.